Literature DB >> 15570661

Disseminated primary varicella infection during infliximab treatment.

Harald Vonkeman1, Chris ten Napel, Hans Rasker, Mart van de Laar.   

Abstract

A young man developed a serious disseminated varicella infection, necessitating antiviral treatment, after being treated with anti-tumor necrosis factor-alpha therapy for rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15570661

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  6 in total

1.  Varicella vaccine safety and immunogenicity in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids.

Authors:  Robert W Frenck; Jane F Seward
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-07       Impact factor: 4.794

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

Review 3.  Tumor necrosis factor blockade and the risk of viral infection.

Authors:  Seo Young Kim; Daniel H Solomon
Journal:  Nat Rev Rheumatol       Date:  2010-02-09       Impact factor: 20.543

4.  Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.

Authors:  Nirmal Kaur; Thomas C Mahl
Journal:  Dig Dis Sci       Date:  2007-04-11       Impact factor: 3.487

5.  A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab - a new side effect after 15 years of usage.

Authors:  Tomislava Skuhala; Anita Atelj; Jelena Prepolec; Mahmoud Al-Mufleh; Andrija Stanimirović; Dalibor Vukelić
Journal:  BMC Infect Dis       Date:  2019-02-07       Impact factor: 3.090

6.  Immunisation status of children and adolescents with a new diagnosis of inflammatory bowel disease.

Authors:  Timothy Ford; Margie Danchin; Alissa McMinn; Kirsten Perrett; George Alex; Nigel W Crawford
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.